Early Detection of Pancreatic Cancer: Prospective Study

What this Trial Is About

Pancreatic ductal adenocarcinoma (PDAC) is a very deadly cancer often detected too late for effective treatment. Researchers are evaluating a new blood test that analyzes tiny particles called exosomes containing microRNAs (miRNAs) to detect PDAC earlier than current methods. This study is a prospective international observational study aiming to confirm if this miRNA signature can identify early-stage PDAC effectively. The study uses a diagnostic test named PANXEON which measures the levels of 13 specific miRNAs—5 circulating freely and 8 inside exosomes—in plasma samples. Participants include individuals both with and without PDAC, divided into training and validation groups. Blood samples will be collected to assess the test's ability to detect pancreatic cancer before treatment begins. Participants will provide blood samples that researchers will analyze using a technique called quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). The main outcome measured is the test's sensitivity over about one year, with secondary outcomes including specificity and accuracy. The study will monitor how well this test distinguishes PDAC patients from those without the disease, aiming to improve early detection.

Pancreatic Cancer Detection Consortium